100 results on '"A., Crinò"'
Search Results
2. Diffuse Pancreatic Serous Cystic Neoplasm: A Rare Cause of Pancreatic Insufficiency
3. The features and clinical outcomes of inflammatory bowel disease associated with autoimmune pancreatitis: A greater awareness is needed
4. Rituximab as Maintenance Therapy in Type 1 Autoimmune Pancreatitis: An Italian Experience
5. Azathioprine Maintenance Therapy to Prevent Relapses in Autoimmune Pancreatitis
6. Acute Hypoxemic Respiratory Failure With Hemoptysis in a Dog Exposed to Copper Sulfate Powder
7. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
8. Efficacy of Endoscopic Minor Papilla Sphincterotomy for Symptomatic Santorinicele
9. Supplement to: Nivolumab versus docetaxel in advanced squamous-cell non--small-cell lung cancer.
10. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
11. Non-Alcoholic Fatty Liver Disease (NAFLD) in children and adolescents with Prader–Willi Syndrome (PWS)
12. STELLAR – A phase II trial of TTFields with chemotherapy for first line treatment of malignant mesothelioma: 215TiP
13. Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials: 141PD
14. A Rare Cause of Life-Threatening Upper Gastrointestinal Bleeding
15. Sleep Disordered Breathing in Patients With Prader–Willi Syndrome: A Multicenter Study
16. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
17. Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients
18. Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors
19. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
20. CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment
21. Pharmacokinetics of Trastuzumab in Haemodialysis
22. Letter to the editor concerning ‘Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA’
23. Dramatic Response to Crizotinib in ROS1 Fluorescent In Situ Hybridization- and Immunohistochemistry-Positive Lung Adenocarcinoma: A Case Series
24. ALK Rearrangement Testing by FISH Analysis in Non–Small-Cell Lung Cancer Patients: Results of the First Italian External Quality Assurance Scheme
25. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
26. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
27. Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients
28. Use of GLP-1 Receptor Agonists in Prader-Willi Syndrome: Report of Six Cases
29. Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases
30. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
31. Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non–Small-Cell Lung Cancer Segregated According to KRAS Mutation Status
32. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
33. Central adrenal insufficiency in young adults with Prader-Willi Syndrome
34. Deconvolution-based assessment of pituitary GH secretion stimulated with GHRH+arginine in Prader-Willi adults and obese controls
35. Recommendations for the Analysis of ALK Gene Rearrangements in Non–Small-Cell Lung Cancer: A Consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology
36. Glyburide ameliorates motor coordination and glucose homeostasis in a child with diabetes associated with the KCNJ11/S225T, del226-232 mutation
37. First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer: Analysis of the Italian Patients Enrolled in the SAiL Study
38. First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer: Analysis of the Italian Patients Enrolled in the SAiL Study
39. First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer: Analysis of the Italian Patients Enrolled in the SAiL Study
40. Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study
41. Novel molecular trends in the management of advanced non-small-cell lung cancer
42. Assessment of central adrenal insufficiency in children and adolescents with Prader–Willi syndrome
43. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
44. Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390)
45. Multiple forms of hypogonadism of central, peripheral or combined origin in males with Prader–Willi syndrome
46. Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients
47. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
48. Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer
49. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine
50. Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.